Adline Chem Lab Stock Screener | Share Price & Fundamental Analysis
ADLINE
Pharmaceuticals
Screen Adline Chem Lab share price with our stock screener - analyze fundamentals and track trades in your journal
Market Cap
₹5.14 Cr.
P/B Ratio
-3.03
EPS (TTM)
₹-0.21
Dividend Yield
-
Debt to Equity
-
52W High
-
52W Low
-
Operating Margin
-
Profit Margin
-
EBITDA
-
Net Income
-
Total Assets
-
Total Equity
₹-2.00
Adline Chem Lab Share Price History - Stock Screener Chart
Screen ADLINE historical share price movements with interactive charts. Analyze price trends and patterns.
Adline Chem Lab Company Profile - Fundamental Screener
Screen Adline Chem Lab company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ADLINE shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE276T01018
Adline Chem Lab Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen ADLINE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 0 | 0 | 0 | 5 | 6 | 8 | 22 | 23 | 21 | 18 |
| Current Assets | 0 | 0 | 0 | 0 | 2 | 3 | 10 | 11 | 8 | 7 |
| Fixed Assets | 0 | 0 | 0 | 4 | 4 | 5 | 12 | 13 | 13 | 10 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 5 | 6 | 8 | 22 | 23 | 21 | 18 |
| Current Liabilities | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 5 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | -2 | -1 | -2 | 3 | 2 | 3 | 7 | 7 | 7 | 7 |
| Share Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves & Surplus | -7 | -7 | -7 | -3 | -4 | -3 | 1 | 1 | 1 | 1 |
Screen ADLINE income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 1 | 6 | 7 | 6 | 8 | 17 | 17 | 15 |
| Expenses | 0 | 0 | 0 | 1 | 1 | 7 | 10 | 5 | 7 | 16 | 17 | 14 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | -3 | 1 | 1 | 1 | 1 | 1 |
| Operating Profit % | 0.00% | 0.00% | 0.00% | 0.00% | -40.00% | -4.00% | -51.00% | 11.00% | 11.00% | 7.00% | 3.00% | 6.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit Before Tax | 0 | 0 | 0 | -4 | 1 | -1 | -4 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | -4 | 1 | -1 | -4 | 0 | 0 | 0 | 0 | 0 |
| EPS | 0.00 | -0.21 | -0.46 | -7.24 | 1.23 | -2.19 | -6.45 | 0.05 | 0.00 | 0.01 | 0.02 | 0.04 |
Adline Chem Lab Cash Flow Screener - Liquidity Fundamentals
Screen ADLINE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 0 | 0 | 0 | 0 | 0 | -11 | -1 | 1 | 3 | 1 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 | -3 | 0 |
| Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | -1 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 2 | 0 | 0 |
Screen ADLINE shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 29.61% | 29.61% | 29.61% | 29.61% | 29.61% | 29.61% | 29.61% | 28.24% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 60.16% | 60.16% | 60.13% | 60.15% | 60.32% | 60.30% | 60.29% | 61.63% |
| Other Holding | 10.23% | 10.23% | 10.26% | 10.24% | 10.07% | 10.09% | 10.10% | 10.14% |
| Shareholder Count | 18,481 | 18,481 | 18,514 | 18,509 | 18,536 | 18,583 | 18,595 | 18,628 |
Adline Chem Lab Dividend Screener - Share Yield Analysis
Screen ADLINE dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Adline Chem Lab Index Membership - Market Screener Classification
Screen ADLINE by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Adline Chem Lab Market Events Screener - Corporate Actions
Screen ADLINE market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Change Of Name | NA | - | ||
| Annual General Meeting | NA | 11.05% | ||
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -9.67% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | 10.23% |
| 2025-07-22 | 2025-07-22 | Annual General Meeting | NA | -1.67% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | 1.95% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | -5.76% |
| 2025-01-16 | 2025-01-16 | Extraordinary General Meeting | NA | 4.36% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -3.92% |
Adline Chem Lab Competitors Screener - Peer Comparison
Screen ADLINE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 424,634 | 39.93 | 54,729 | 9.71% | 10,980 | 49.55 |
| Divis Laboratories | 172,860 | 69.20 | 9,712 | 18.67% | 2,191 | 56.33 |
| Torrent Pharmaceuticals | 129,151 | 60.10 | 11,539 | 6.99% | 1,911 | 61.47 |
| Cipla | 122,205 | 22.55 | 28,410 | 7.12% | 5,291 | 49.47 |
| Dr Reddys Laboratories | 107,114 | 18.60 | 33,741 | 16.73% | 5,725 | 60.05 |
| Lupin | 97,120 | 22.34 | 22,910 | 13.74% | 3,306 | 65.28 |
| Zydus Life Science | 92,392 | 18.40 | 23,511 | 18.55% | 4,615 | 40.07 |
| Mankind Pharma | 90,241 | 50.59 | 12,744 | 20.90% | 2,007 | 45.53 |
| Aurobindo Pharma | 71,119 | 20.79 | 32,346 | 9.43% | 3,484 | 59.88 |
| Alkem Laboratories | 67,243 | 27.59 | 13,458 | 3.70% | 2,216 | 49.80 |
Adline Chem Lab Company Announcements - News Screener
Screen ADLINE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-11-26 | Intimation Of Receipt Of Approval For Reclassification Application Of Promoter Under Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Resignation of Chairman and Managing Director | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Resignation of Director | View |
| 2025-11-12 | Unaudited Standalone Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September 2025 | View |
| 2025-11-12 | Board Meeting Outcome for Board Meeting Outcome For Unaudited Standalone Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September 2025 | View |
| 2025-11-05 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-10-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Closure of Trading Window | View |
| 2025-08-14 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | View |
| 2025-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-12 | Unaudited Standalone Financial Results Of The Company For The Quarter Ended June 30 2025 | View |
| 2025-08-12 | Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting For Unaudited Standalone Financial Results Of The Company For The Quarter Ended June 30 2025 | View |
| 2025-08-05 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone Financial Results For The Quarter Ended On 30Th June 2025. | View |
| 2025-07-23 | Scrutinizer"S Report | View |
| 2025-07-22 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-07-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-06-28 | Reg. 34 (1) Annual Report. | View |
| 2025-06-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-06-27 | AGM OF THE COMPANY SCHEDULED TO BE HELD ON TUESDAY 22ND JULY 2025 AT 02:00 P.M. | View |